317830-29-8

Basic information

• Product Name: (R)-3-(1-AMINOETHYL)BENZENAMINE
• Synonyms: (R)-3-AMINO-ALFA-METHYL-BENZENEMETHANAMINE;(R)-3-AMINO-ALFA-METHYLBENZENEMETHANEAMINE;(R)-3-AMINO-ALPHA-METHYL-BENZENEMETHANAMINE;Benzenemethanamine, 3-amino-alpha-methyl-, (alphaS)- (9CI);(R)-2-AMINO-ALPHA-METHYLBENZENEMETHANAMINE;Benzenemethanamine, 3-amino-α-methyl-, (αS)-;3-aMino-a-Methyl-;BenzeneMethanaMine, 3-aMino-a-Methyl-, (aS)-
• CAS NO: 317830-29-8
• Molecular Formula: C₈H₁₂N₂
• Molecular Weight: 136.19
• Product Categories: AMINEPRIMARY
• Mol File: 317830-29-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 266.46 °C at 760 mmHg
• Flash Point: 135.199 °C
• Appearance: /
• Density: 1.056 g/cm³
• Vapor Pressure: 0.00863mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.06±0.10(Predicted)
• CAS DataBase Reference: (R)-3-(1-AMINOETHYL)BENZENAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-(1-AMINOETHYL)BENZENAMINE(317830-29-8)
• EPA Substance Registry System: (R)-3-(1-AMINOETHYL)BENZENAMINE(317830-29-8)

Safety Data

• Hazardous Substances Data: 317830-29-8(Hazardous Substances Data)

Usage

General Description

The chemical compound (R)-3-(1-aminoethyl)benzenamine, also known as R (+) 1-(3-aminophenyl)ethanol, is an organic compound belonging to the class of aromatic amines. It consists of a benzene ring attached to an aminoethyl group, with the amine group in the para-position to the hydroxyl group. (R)-3-(1-AMINOETHYL)BENZENAMINE can be used as a chiral ligand in asymmetric synthesis and as a building block in the synthesis of various pharmaceutical compounds and fine chemicals. It has also been investigated for its potential use in the treatment of neurodegenerative diseases and as a reactive moiety in the development of new materials. Due to its structural and functional properties, (R)-3-(1-aminoethyl)benzenamine has found diverse applications in the fields of chemistry, pharmacology, and materials science.

InChI:InChI=1/C8H12N2/c1-6(9)7-3-2-4-8(10)5-7/h2-6H,9-10H2,1H3/t6-/m1/s1

Upstream product

• 5400-78-2 1-(3-nitrophenyl)ethanol 
• 90271-37-7 3-nitro-α-methylbenzylamine 
• 246240-16-4 1-(1-azidoethyl)-3-nitrobenzene 
• 121-89-1 3-Nitroacetophenone 
• 90271-37-7 (S)-1-(3 -nitrophenyl)ethan-1-amine 

Downstream Products

• 317830-31-2 2-[(S)-1-(3-aminophenyl)ethylamino]-4-[benzimidazol-1-yl]pyrimidine 
• 1027255-35-1 (S)-N-[1-(3-aminophenyl)ethyl]-6-chloropyrazin-2-amine 
• 1610766-73-8 C₁₄H₁₉N₃O₂ 
• 1610766-85-2 C₂₃H₂₆N₄O₄ 
• 1610766-84-1 C₂₇H₃₄N₄O₅ 
• 1610766-83-0 C₂₇H₃₂N₄O₅ 
• 1610766-82-9 C₂₆H₃₃N₅O₅ 
• 1610766-74-9 C₂₁H₂₃N₃O₄ 
• 1610766-81-8 C₂₃H₂₈N₄O₄ 
• 1610766-80-7 (2R)-1-cyanobutan-2-yl-[(1S)-1-(3-{[(3,4-dimethoxyphenyl)carbamoyl]amino}phenyl)ethyl] carbamate 
• 1610767-25-3 C₂₉H₂₈N₆O₃ 
• 1610767-23-1 C₂₇H₂₆N₆O₄ 
• 1610767-19-5 C₂₇H₃₂N₆O₄ 
• 1610767-18-4 C₂₃H₂₈N₄O₇S 

Relevant articles and documents

Design, synthesis and biological evaluation of novel inosine 5′-monophosphate dehydrogenase (IMPDH) inhibitors

This study is based on our attempts to further explore the structure-activity relationship (SAR) of VX-148 (3) in an attempt to identify inosine 5′-mono-phosphate dehydrogenase (IMPDH) inhibitors superior to mycophenolic acid. A five-point pharmacophore developed using structurally diverse, known IMPDH inhibitors guided further design of novel analogs of 3. Several conventional as well as novel medicinal chemistry strategies were tried. The combined structure- and ligand-based approaches culminated in a few analogs with either retained or slightly higher potency. The compounds which retained the potency were also checked for their ability to inhibit human peripheral blood mononuclear cells proliferation. This study illuminates the stringent structural requirements and strict SAR for IMPDH II inhibition.

INHIBITORS OF KINASE ACTIVITY

The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLTl, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDRl and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases.